Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with …
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development – Oncology
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record …
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala
Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video hereBOSTON and LONDON – …
Welcome from Abizer Gaslightwala, President and CEO
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer …
